Start reading ,This title and over 12000 thousand more,available with Avenue Library, T&C*
Japan Orphan Drugs Market - Opportunity Analysis and Industry Forecast, 2018-2025
| A04486 | Pages: NA | Aug 2021 | 1031 Views | | |
| Author(s) : NA | Tables: NA | Charts: NA | Formats*: | |
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. PORTER’S FIVE FORCES ANALYSIS
3.4. PATENT ANALYSIS
3.5. REGULATIONS
3.6. MARKET DYNAMICS
3.6.1. Drivers
3.6.2. Restraints
3.6.3. Opportunities
CHAPTER 4 JAPAN ORPHAN DRUGS MARKET, BY DISEASE TYPE
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. ONCOLOGIC DISEASES
4.2.1. Key market trends, growth factors & opportunities
4.2.2. Market size and forecast
4.3. METABOLIC DISEASES
4.3.1. Key market trends, growth factors & opportunities
4.3.2. Market size and forecast
4.4. HEMATOLOGIC AND IMMUNOLOGIC DISEASES
4.4.1. Key market trends, growth factors & opportunities
4.4.2. Market size and forecast
4.5. INFECTIOUS DISEASES
4.5.1. Key market trends, growth factors & opportunities
4.5.2. Market size and forecast
4.6. NEUROLOGIC DISEASES
4.6.1. Key market trends, growth factors & opportunities
4.6.2. Market size and forecast
4.7. OTHER RARE DISEASES
4.7.1. Key market trends, growth factors & opportunities
4.7.2. Market size and forecast
CHAPTER 5 JAPAN ORPHAN DRUGS MARKET, BY INDICATION
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. NON-HODGKIN LYMPHOMA
5.2.1. Market size and forecast
5.3. ACUTE MYELOID LEUKEMIA
5.3.1. Market size and forecast
5.4. CYSTIC FIBROSIS
5.4.1. Market size and forecast
5.5. GLIOMA
5.5.1. Market size and forecast
5.6. PANCREATIC CANCER
5.6.1. Market size and forecast
5.7. OVARIAN CANCER
5.7.1. Market size and forecast
5.8. MULTIPLE MYELOMA
5.8.1. Market size and forecast
5.9. DUCHENNE MUSCULAR DYSTROPHY
5.9.1. Market size and forecast
5.10. GRAFT VS HOST DISEASE
5.10.1. Market size and forecast
5.11. RENAL CELL CARCINOMA
5.11.1. Market size and forecast
5.12. OTHERS
5.12.1. Market size and forecast
CHAPTER 6 COMPANY PROFILES
6.1. ABBVIE INC.
6.1.1. Operating business segments
6.1.2. Business performance
6.1.3. Key strategic moves and developments
6.2. AEGERION PHARMACEUTICALS, INC. (NOVELION THERAPEUTICS INC.)
6.2.1. Operating business segments
6.2.2. Business performance
6.2.3. Key strategic moves and developments
6.3. BRISTOL-MYERS SQUIBB COMPANY
6.3.1. Operating business segments
6.3.2. Business performance
6.3.3. Key strategic moves and developments
6.4. CELGENE CORPORATION
6.4.1. Operating business segments
6.4.2. Business performance
6.4.3. Key strategic moves and developments
6.5. F. HOFFMANN-LA ROCHE AG
6.5.1. Operating business segments
6.5.2. Business performance
6.5.3. Key strategic moves and developments
6.6. GLAXOSMITHKLINE PLC
6.6.1. Operating business segments
6.6.2. Business performance
6.6.3. Key strategic moves and developments
6.7. JOHNSON & JOHNSON
6.7.1. Operating business segments
6.7.2. Business performance
6.7.3. Key strategic moves and developments
6.8. NOVARTIS AG
6.8.1. Operating business segments
6.8.2. Business performance
6.8.3. Key strategic moves and developments
6.9. PFIZER INC.
6.9.1. Operating business segments
6.9.2. Business performance
6.9.3. Key strategic moves and developments
6.10. SANOFI
6.10.1. Operating business segments
6.10.2. Business performance
6.10.3. Key strategic moves and developments
We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:
- Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
- Technologically sophisticated and reliable insights through well audited and veracious research methodology
- Sovereign research proceeds that present a tangible depiction of marketplace
With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.
Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, web-casts and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast
Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develops analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth and forecasts
Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:
- Chief executives and VPs of leading corporations specific to industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)
Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.
Access from any device, anywhere
Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.
REQUEST TOC/SAMPLE
Purchase Full Report of
Japan Orphan Drugs Market- Opportunity Analysis and Industry Forecast, 2018-2025
- Online Only
-
$3,456$3,110 - Online cloud access only
- Restricted print, copy, paste & download
- Read only
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
10%
Discount
- Data Pack
-
$3,840$3,456 - Restricted to one authorized user
- One print only
- Available in
Excel - Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
10%
Discount
- Single User
-
$5,769$5,192 - Restricted to one authorized user
- One print only
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
10%
Discount
- Five Users
-
$6,450$5,805 - Limited to five authorized users
- Print upto five copies
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
10%
Discount
-
Enterprise
License/PDF -
$8,995$8,096 - Unlimited
within
company/enterprise - Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
10%
Discount
- Library Membership
- $ 699/mo
- Published Content
E-access - Company Profiles
E-access - Newly Added Content Access
- 10 PDF
Downloads - 5 Excel Data
Pack Downloads - 250 Company Profiles PDF Downloads
-
Start reading.
Buy Now
This title and over 12,000+ are available on the Avenue Library. T&C*.
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
Why Allied Market Research?
Infallible Methodology
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
Analyst Support
For complete satisfaction
Customization
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET VIEW
Targeted market view to provide pertinent information and save time of readers
Get fresh content delivered
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Why Allied Market Research?
Infallible Methodology
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
Analyst Support
For complete satisfaction
Customization
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET VIEW
Targeted market view to provide pertinent information and save time of readers